Active agent-releasing dosage forms

• US 20080026040A1
• Filed: 07/31/2006
• Published: 01/31/2008
• Est. Priority Date: 07/31/2006
• Status: Abandoned Application

• Current Assignee: Iddys D. Figueroa, Isaac Farr, Javier Valentin-Sivico, Kevin Michael Kane, Leslie Rivera Guzman, Mirayda Aponte, Ricardo G. Diaz-Felipe, Saul Tirado
• Original Assignee: Iddys D. Figueroa, Isaac Farr, Javier Valentin-Sivico, Kevin Michael Kane, Leslie Rivera Guzman, Mirayda Aponte, Ricardo G. Diaz-Felipe, Saul Tirado
• Inventors: Kane, Kevin Michael, Aponte, Mirayda, Tirado, Saul, Valentin-Sivico, Javier, Rivera Guzman, Leslie, Diaz-Felipe, Ricardo G., Farr, Isaac, Figueroa, Iddys D.
• Application Number:
  US11/496,770
• Publication Number:
  US 20080026040A1
• Time in Patent Office: Days
• US Class Current: 424/443
• CPC Class Codes: A61K 31/18 Sulfonamides compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61K 9/7092 Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides pharmaceutical compositions. In one aspect, a pharmaceutical composition is provided having a plurality of polymeric film layers heat sealed together as a multilayer structure and having an active agent dispersed within the multilayer structure. The multilayer structure is configured to release the active agent upon administration to a subject, either in a controlled release or immediate release manner.

Claims

1. A pharmaceutical composition, comprising:

a plurality of polymeric film layers heat sealed together as a multilayer structure; and

controlled amounts of active agent dissolved or dispersed in a liquid vehicle which have been ink-jetted on at least one of the plurality of polymeric film layers prior to being heat sealed together, wherein the active agent is within the multilayer structure.

2. The composition of claim 1, wherein the plurality of polymeric film layers include a member selected from hydroxylpropylmethylcellulose, hydroxylpropylcellulose, carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose, high molecular weight polyethylene oxide, polyvinyl alcohol, polymethylvinylether, poly-(2-ethyl 2-oxazoline), polysaccharides, sodium alginate, polymethacrylates, polyvinylpyrrolidone, polyacrylic acid, polyesters, polylactic acid, poly(lactide-co-glycolide), polycaprolactone, polyglycolic acid, natural or chemically modified starches, polyethylene glycol, polyethylene oxide, 2-methyloxirane, oxirane, glycerin based materials, gelatin, wheat gluten, pectin, xanthan gum, guar gum, algin, chitosan, pullulan, sorbitol, seaweed, milk proteins, rice paper, potato wafer sheets, restructured fruits and vegetables, and combinations thereof.

3. The composition of claim 1, wherein the plurality of polymeric film layers includes pullulan.

4. The composition of claim 1, wherein the plurality of polymeric film layers includes polyvinylpyrrolidone.

5. The composition of claim 1, wherein the active agent is dispersed within only a portion of the multilayer structure.

6. The composition of claim 1, wherein the active agent includes a member selected from amiodarone HCL, atorvastatin, candesartan, carvedilol, clopidogrel bisulfate, dipyridamole, eprosartan mensylate, felodipine, furosemide, isradipine, lovastatin, metolazone, propafenone HCL, quinapril, ramipril, simvastatin, trandolapril, valsartan, clozapine, entacapone, fluphenazine, fluvoxamine, imipramine, olanzapine, paroxetine, sertraline, triazolam, zaleplon, ziprasidone, acyclovir, amphotericin B, amprenavir, cefdinir, cefixime, ceftazidime, clarithromycin, didanosine, efavirenz, ganciclovir, itraconazole, melfloquine, norfloxacin, nystatin, ritonavir, saquinavir, tenofovir disoproxil fumarate, beclomethasone dipropionate, bosentan, budesonide, fexofenadine, flunisolide, fluticasone, loratadine, mometasone, salmeterol xinafoate, triamcinolone acetonide, zafirlukast, celecoxib, diclofenac sodium, dihydroergotamine mesylate, ergoloid mesylates, ergotamine tartrate, fentanyl citrate, nabumetone, azathioprine, carboplatin, cisplatin, cyclosporine, docetaxel, etoposide, flurouracil, irinotecan, letrozole, melphalan, mitotane, paclitaxel, pimecrolimus, sirolimus, tacrolimus, valrubicin, ethinyl estradiol, danazol, follotropin beta, medroxy-progesterone, methyl-testosterone, raloxifene HCL, sildenafil citrate, testosterone, calcitrol, dronabinol, famotidine, glyburide, isotretinoin, megestrol, modafinil, nimodipine, pioglitazone, propofol, thalidomide, betamethasone, triamcinolone, piroxicam, glimepiride, glipizide, digoxin, prednisolone, indomethacine, nadolol, fluconazol, cisapride, ibuprofen, acetaminophen, carbamazepine, nifedipine, ketoprofen, and derivatives, prodrugs, mixtures, and combinations thereof.

7. The composition of claim 1, wherein the active agent is located substantially between adjacent polymeric film layers.

8. The composition of claim 1, wherein at least a portion of the active agent is absorbed into at least one of the plurality of polymeric film layers.

9. The composition of claim 1, wherein the pharmaceutical composition is formulated as a transdermal or transmucosal dosage form.

10. The composition of claim 1, wherein the pharmaceutical composition is formulated as an oral dosage form.

11. The composition of claim 1, wherein active agent is absent in those regions of the multilayer structure having polymeric film layers heat sealed directly together.

12. The composition of claim 1, wherein the active agent is dissolved in the liquid vehicle.

13. The composition of claim 12, wherein upon jetting the dissolved active agent on the at least one of the plurality of polymeric film layers, the active agent forms nanoparticles.

14. The composition of claim 1, wherein the plurality of polymeric film layers includes at least three layers of the same material.

15. The composition of claim 1, wherein the active agent is precisely printed via control from a digital source to generate a predetermined pattern of active agent within the multilayer structure.

16. The composition of claim 1, in controlled release form.

17. The composition of claim 1, in an immediate release form.

18. A method of making a pharmaceutical composition, comprising:

dispersing or dissolving an active agent in a liquid vehicle to form an ink-jettable composition;

precisely ink-jetting the ink-jettable composition on at least one of a plurality of polymeric film layers; and

heat sealing the plurality of polymeric film layers into a multilayer structure.

19. The method of claim 18, wherein the active agent is dissolved in the liquid vehicle.

20. The method of claim 19, wherein after ink-jetting the ink-jettable composition on the at least one of the plurality of polymeric film layers, the active agent comes out of solution and forms nanoparticles.

21. The method of claim 18, wherein the step of ink-jetting the ink-jettable composition includes avoiding printing in areas where heat sealing occurs.

22. The method of claim 18, wherein the step of printing is by a thermal ink-jet printing process.

23. The method of claim 18, wherein the step of printing is by a piezo ink-jet printing process.

24. The method of claim 18, wherein the active agent includes a member selected from amiodarone HCL, atorvastatin, candesartan, carvedilol, clopidogrel bisulfate, dipyridamole, eprosartan mensylate, felodipine, furosemide, isradipine, lovastatin, metolazone, propafenone HCL, quinapril, ramipril, simvastatin, trandolapril, valsartan, clozapine, entacapone, fluphenazine, fluvoxamine, imipramine, olanzapine, paroxetine, sertraline, triazolam, zaleplon, ziprasidone, acyclovir, amphotericin B, amprenavir, cefdinir, cefixime, ceftazidime, clarithromycin, didanosine, efavirenz, ganciclovir, itraconazole, melfloquine, norfloxacin, nystatin, ritonavir, saquinavir, tenofovir disoproxil fumarate, beclomethasone dipropionate, bosentan, budesonide, fexofenadine, flunisolide, fluticasone, loratadine, mometasone, salmeterol xinafoate, triamcinolone acetonide, zafirlukast, celecoxib, diclofenac sodium, dihydroergotamine mesylate, ergoloid mesylates, ergotamine tartrate, fentanyl citrate, nabumetone, azathioprine, carboplatin, cisplatin, cyclosporine, docetaxel, etoposide, flurouracil, irinotecan, letrozole, melphalan, mitotane, paclitaxel, pimecrolimus, sirolimus, tacrolimus, valrubicin, ethinyl estradiol, danazol, follotropin beta, medroxy-progesterone, methyl-testosterone, raloxifene HCL, sildenafil citrate, testosterone, calcitrol, dronabinol, famotidine, glyburide, isotretinoin, megestrol, modafinil, nimodipine, pioglitazone, propofol, thalidomide, betamethasone, triamcinolone, piroxicam, glimepiride, glipizide, digoxin, prednisolone, indomethacine, nadolol, fluconazol, cisapride, ibuprofen, acetaminophen, carbamazepine, nifedipine, ketoprofen, and derivatives, prodrugs, mixtures, and combinations thereof.

25. The method of claim 18, wherein the plurality of polymeric film layers include a member selected from hydroxylpropylmethylcellulose, hydroxylpropylcellulose, carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose, high molecular weight polyethylene oxide, polyvinyl alcohol, polymethylvinylether, poly-(2-ethyl 2-oxazoline), polysaccharides, sodium alginate, polymethacrylates, polyvinylpyrrolidone, polyacrylic acid, polyesters, polylactic acid, poly(lactide-co-glycolide), polycaprolactone, polyglycolic acid, natural or chemically modified starches, polyethylene glycol, polyethylene oxide, 2-methyloxirane, oxirane, glycerin based materials, gelatin, wheat gluten, pectin, xanthan gum, guar gum, algin, chitosan, pullulan, sorbitol, seaweed, milk proteins, rice paper, potato wafer sheets, restructured fruits and vegetables, and combinations thereof.

26. The method of claim 18, wherein the plurality of polymeric film layers includes pullulan.

27. The method of claim 18, wherein the plurality of polymeric film layers includes polyvinylpyrrolidone.

28. The method of claim 18, wherein the pharmaceutical composition is formulated in a controlled release form.

29. The method of claim 18, wherein the pharmaceutical composition is formulated in an immediate release form.

30. A method of using a pharmaceutical composition, comprising administering to a subject a pharmaceutical composition including:

a plurality of polymeric film layers heat sealed together as a multilayer structure; and

controlled amounts of active agent dissolved or dispersed in a liquid vehicle which have been ink-jetted on at least one of the plurality of polymeric film layers prior to being heat sealed together, wherein the active agent is within the multilayer structure.

31. The method of claim 30, wherein the pharmaceutical composition is administered to the subject as a transdermal dosage form.

32. The method of claim 30, wherein the pharmaceutical composition is administered to the subject as an oral dosage form.

33. The method of claim 30, wherein the pharmaceutical composition is administered to the subject as a transmucosal dosage form.

34. The method of claim 30, wherein the active agent is selected from amiodarone HCL, atorvastatin, candesartan, carvedilol, clopidogrel bisulfate, dipyridamole, eprosartan mensylate, felodipine, furosemide, isradipine, lovastatin, metolazone, propafenone HCL, quinapril, ramipril, simvastatin, trandolapril, valsartan, clozapine, entacapone, fluphenazine, fluvoxamine, imipramine, olanzapine, paroxetine, sertraline, triazolam, zaleplon, ziprasidone, acyclovir, amphotericin B, amprenavir, cefdinir, cefixime, ceftazidime, clarithromycin, didanosine, efavirenz, ganciclovir, itraconazole, melfloquine, norfloxacin, nystatin, ritonavir, saquinavir, tenofovir disoproxil fumarate, beclomethasone dipropionate, bosentan, budesonide, fexofenadine, flunisolide, fluticasone, loratadine, mometasone, salmeterol xinafoate, triamcinolone acetonide, zafirlukast, celecoxib, diclofenac sodium, dihydroergotamine mesylate, ergoloid mesylates, ergotamine tartrate, fentanyl citrate, nabumetone, azathioprine, carboplatin, cisplatin, cyclosporine, docetaxel, etoposide, flurouracil, irinotecan, letrozole, melphalan, mitotane, paclitaxel, pimecrolimus, sirolimus, tacrolimus, valrubicin, ethinyl estradiol, danazol, follotropin beta, medroxy-progesterone, methyl-testosterone, raloxifene HCL, sildenafil citrate, testosterone, calcitrol, dronabinol, famotidine, glyburide, isotretinoin, megestrol, modafinil, nimodipine, pioglitazone, propofol, thalidomide, betamethasone, triamcinolone, piroxicam, glimepiride, glipizide, digoxin, prednisolone, indomethacine, nadolol, fluconazol, cisapride, ibuprofen, acetaminophen, carbamazepine, nifedipine, ketoprofen, and derivatives, prodrugs, mixtures, and combinations thereof.

35. The method of claim 30, wherein the plurality of polymeric film layers include a member selected from hydroxylpropylmethylcellulose, hydroxylpropylcellulose, carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose, high molecular weight polyethylene oxide, polyvinyl alcohol, polymethylvinylether, poly-(2-ethyl 2-oxazoline), polysaccharides, sodium alginate, polymethacrylates, polyvinylpyrrolidone, polyacrylic acid, polyesters, polylactic acid, poly(lactide-co-glycolide), polycaprolactone, polyglycolic acid, natural or chemically modified starches, polyethylene glycol, polyethylene oxide, 2-methyloxirane, oxirane, glycerin based materials, gelatin, wheat gluten, pectin, xanthan gum, guar gum, algin, chitosan, pullulan, sorbitol, seaweed, milk proteins, rice paper, potato wafer sheets, restructured fruits and vegetables, and combinations thereof.

36. The method of claim 30, wherein active agent is absent in those regions of the multilayer structure having polymeric film layers heat sealed directly together.

37. The method of claim 30, wherein the active agent is dissolved in the liquid vehicle.

38. The method of claim 37, wherein upon jetting the dissolved active agent on the at least one of the plurality of polymeric film layers, the active agent forms nanoparticles.

39. The method of claim 30, wherein the plurality of polymeric film layers includes at least three layers of the same material.

40. A system for making a pharmaceutical composition, comprising:

an ink-jetting means for digitally applying an active agent to only a portion of at least one of a plurality of polymeric film layers; and

a heat sealing means for bonding the plurality of polymeric film layers into a multilayer structure such that the heat sealing occurs only where no active agent is present in the multilayer structure.